Torii Pharmaceutical Co Ltd
TSE:4551

Watchlist Manager
Torii Pharmaceutical Co Ltd Logo
Torii Pharmaceutical Co Ltd
TSE:4551
Watchlist
Price: 6 330 JPY Market Closed
Market Cap: 182.3B JPY

Torii Pharmaceutical Co Ltd
Short-Term Investments

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Torii Pharmaceutical Co Ltd
Short-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
Torii Pharmaceutical Co Ltd
TSE:4551
Short-Term Investments
ÂĄ29B
CAGR 3-Years
-10%
CAGR 5-Years
-5%
CAGR 10-Years
5%
Takeda Pharmaceutical Co Ltd
TSE:4502
Short-Term Investments
ÂĄ58.2B
CAGR 3-Years
22%
CAGR 5-Years
31%
CAGR 10-Years
0%
Daiichi Sankyo Co Ltd
TSE:4568
Short-Term Investments
ÂĄ51.4B
CAGR 3-Years
-48%
CAGR 5-Years
-35%
CAGR 10-Years
-20%
Otsuka Holdings Co Ltd
TSE:4578
Short-Term Investments
ÂĄ27.1B
CAGR 3-Years
16%
CAGR 5-Years
-13%
CAGR 10-Years
-14%
Chugai Pharmaceutical Co Ltd
TSE:4519
Short-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Astellas Pharma Inc
TSE:4503
Short-Term Investments
ÂĄ8.7B
CAGR 3-Years
-35%
CAGR 5-Years
2%
CAGR 10-Years
-11%
No Stocks Found

Torii Pharmaceutical Co Ltd
Glance View

Market Cap
178B JPY
Industry
Pharmaceuticals

Torii Pharmaceutical Co., Ltd. engages in the manufacturing and marketing of pharmaceutical products. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 560 full-time employees. The company went IPO on 2013-10-01. The Company’s main product categories include oral pruritus improving agents, proteolytic enzyme inhibitors, hyperkalemia improving agents, topical adrenocortical hormones, allergen immunotherapy for cedar pollinosis, allergen immunotherapy for mite allergy, active viable bacterial preparations, uterine contraction inhibitors in premature birth and others. The Company’s main products include Remitch, Riona tablets, Keixalate, Yulinome tablets, Antebate, Locoid, Zefnate, Sida Torengi pollen sublingual solution, Miticure mite sublingual tablet, Biosley, Magcent and others.

Intrinsic Value
3 854.39 JPY
Overvaluation 39%
Intrinsic Value
Price

See Also

What is Torii Pharmaceutical Co Ltd's Short-Term Investments?
Short-Term Investments
29B JPY

Based on the financial report for Jun 30, 2025, Torii Pharmaceutical Co Ltd's Short-Term Investments amounts to 29B JPY.

What is Torii Pharmaceutical Co Ltd's Short-Term Investments growth rate?
Short-Term Investments CAGR 10Y
5%

Over the last year, the Short-Term Investments growth was -26%. The average annual Short-Term Investments growth rates for Torii Pharmaceutical Co Ltd have been -10% over the past three years , -5% over the past five years , and 5% over the past ten years .

Back to Top